Animal studies have demonstrated that intravenous infusion of ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) increase the prevalence of ACE2 in the cardiopulmonary circulation.10 This led to growing concerns that medications acting on the renin-angiotensin-aldosterone system increased the risk of patients contracting COVID-19 or having a more severe illness. The gene discussed is REN; the disease is COVID-19.